BusinessGlobal Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)By Nasdaq OMXSep 5, 2017, 12:01 PM UTC
BusinessGlobal Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in SeptemberBy Nasdaq OMXAug 30, 2017, 8:05 PM UTC
BusinessGlobal Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare ConferenceBy Nasdaq OMXAug 9, 2017, 8:05 PM UTC
BusinessGlobal Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial ResultsBy Nasdaq OMXAug 7, 2017, 8:05 PM UTC
BusinessGlobal Blood Therapeutics Announces New Employment Inducement GrantsBy Nasdaq OMXJul 26, 2017, 8:05 PM UTC
BusinessGlobal Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric PopulationBy Nasdaq OMXJul 10, 2017, 12:00 PM UTC
BusinessGlobal Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)By Nasdaq OMXJun 28, 2017, 12:00 PM UTC
BusinessGlobal Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell DiseaseBy Nasdaq OMXJun 23, 2017, 6:30 AM UTC
